What is Ecnoglutide?
Ecnoglutide (development codes XW003 / PB-119) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences. It is engineered as a biased agonist that preferentially activates cAMP signaling over β-arrestin recruitment downstream of the GLP-1 receptor — a design choice intended to optimize the metabolic benefit while reducing receptor desensitization that may limit chronic GLP-1 efficacy.
Ecnoglutide was approved by China's NMPA in 2025 for chronic weight management.
Structure and Pharmacology
Ecnoglutide is a synthetic peptide based on the GLP-1 backbone, modified with a C18 fatty acid acyl chain (similar in concept to the fatty-acid acylation used in semaglutide) to bind albumin and extend half-life to support once-weekly subcutaneous dosing.
The defining pharmacological feature is biased agonism:
- Stronger cAMP/PKA pathway activation — drives the canonical metabolic effects (insulin secretion, glucagon suppression, central anorexigenic signaling)
- Reduced β-arrestin recruitment — less receptor internalization, slower receptor desensitization
The hypothesis is that biased GLP-1 agonists may produce more sustained metabolic effects with less tachyphylaxis over chronic dosing, though clinical confirmation that biased agonism produces superior outcomes vs balanced agonists (semaglutide) is still emerging.
Clinical Evidence
SLIMMER Phase 3 (Lancet Diabetes & Endocrinology 2025):
- Chinese adults with overweight or obesity, randomized to ecnoglutide once weekly vs placebo for 48 weeks
- Significant weight loss vs placebo across multiple dose levels
- Improvements in waist circumference, glycemic markers, lipids, and blood pressure
- Adverse event profile consistent with GLP-1 class (gastrointestinal predominant)
Detailed efficacy magnitudes were broadly comparable to other once-weekly GLP-1 monotherapies; ecnoglutide's distinctive feature is its tolerability profile and the biased-agonism mechanism.
Approval History
- 2025 — NMPA (China) approval for chronic weight management
- No FDA or EMA filings as of mid-2026
Sciwind has signaled intent to pursue out-licensing for ex-China commercialization but has not announced a partner or regulatory timeline outside Greater China.
Place in Therapy
In China, ecnoglutide is positioned as a once-weekly GLP-1 monotherapy option for chronic weight management, competing with locally-marketed semaglutide and the newly approved mazdutide. The biased-agonism design and Chinese-population-specific clinical data give it a differentiated profile in the local market.
Safety Profile
The adverse event profile mirrors the GLP-1 class:
- Nausea, vomiting, diarrhea (most common, dose-titration dependent)
- Decreased appetite (intended pharmacology)
- Injection-site reactions
- Class warnings for pancreatitis, gallbladder disease, and thyroid C-cell tumors (rodent data) apply
Why It Matters
Ecnoglutide is one of two GLP-1-class peptides approved in China in 2025 (the other being mazdutide), reflecting the rapid maturation of the Chinese pipeline in metabolic peptides. It represents a meaningful test of whether biased-agonist design at the GLP-1 receptor produces clinically distinguishable outcomes vs balanced agonists like semaglutide — a question with broader implications for next-generation incretin design.